Product News

Share this article:
FDA accepted Amgen's Biolgoics License Application (BLS) for denosumab, an investigation drug seeking indication for the treatment and prevention of postmenopausal osteoporosis in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer.  Last July, IMS Health said denosumab had blockbuster potential, and could net sales over $1 billion.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.